157 related articles for article (PubMed ID: 28510518)
1. Biosimilar Makers Hope Court Starts 6-Month Wait Sooner.
Silverman E
Manag Care; 2017 Mar; 26(3):31. PubMed ID: 28510518
[TBL] [Abstract][Full Text] [Related]
2. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
Epstein RA
Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851
[TBL] [Abstract][Full Text] [Related]
3. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
Dougherty MP
Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
[TBL] [Abstract][Full Text] [Related]
4. First biosimilar drug set to enter US market.
Ledford H
Nature; 2015 Jan; 517(7534):253-4. PubMed ID: 25592512
[No Abstract] [Full Text] [Related]
5. Patent litigation could make 2017 no 'dancing' matter.
Reinke T
Manag Care; 2016 Dec; 25(12):23-28. PubMed ID: 28121555
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
7. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
8. First biosimilar drug approved for sale in the United States.
Hede K
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444
[No Abstract] [Full Text] [Related]
9. Strategic considerations under the Biologics Price Competition and Innovation Act.
Marquardt JL; Auten SR
Expert Opin Ther Pat; 2013 Aug; 23(8):915-8. PubMed ID: 23829693
[TBL] [Abstract][Full Text] [Related]
10. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon AM
Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
[No Abstract] [Full Text] [Related]
11. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
12. Bracing for the biosimilar wave.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):152-154. PubMed ID: 28248938
[No Abstract] [Full Text] [Related]
13. Are biosimilars patentable?
Rolfe D; Parker J; Morgan M
Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceuticals and medical devices: business practices. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
[No Abstract] [Full Text] [Related]
15. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.
Carver KH; Elikan J; Lietzan E
Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247
[TBL] [Abstract][Full Text] [Related]
16. White paper: an outlook on U.S. biosimilar competition.
Bourgoin AF; Nuskey B
Drugs Today (Barc); 2013 Jun; 49(6):399-410. PubMed ID: 23807943
[TBL] [Abstract][Full Text] [Related]
17. Patent watch: Have the biosimilar floodgates been opened in the United States?
Brinckerhoff CC; Schorr K
Nat Rev Drug Discov; 2015 May; 14(5):303-4. PubMed ID: 25924576
[No Abstract] [Full Text] [Related]
18. Using Data Exclusivity Grants to Incentivize Cumulative Innovation of Biologics' Manufacturing Processes.
Levi EL
Am Univ Law Rev; 2017; 66(3):911-70. PubMed ID: 28233970
[TBL] [Abstract][Full Text] [Related]
19. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
20. Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle?
Reinke T
Manag Care; 2017 Mar; 26(3):20-23. PubMed ID: 28510515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
